Search Results for "Lupus"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lupus. Results 31 to 40 of 49 total matches.

Talicia - A 3-Drug Combination for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
. Acute interstitial nephritis has occurred with both omeprazole and amoxicillin. PPI-induced lupus ...
The FDA has approved a fixed-dose combination of omeprazole, amoxicillin, and rifabutin (Talicia – RedHill) for treatment of Helicobacter pylori infection in adults. Talicia is the first rifabutin-based product to be approved for this indication.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-5 |  Show IntroductionHide Introduction

Certolizumab (Cimzia) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
developed a lupus-like syndrome. 7 DOSAGE AND ADMINISTRATION — Certolizumab is administered as a 400-mg ...
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81-2 |  Show IntroductionHide Introduction

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
has not been established Rarely induces or exacerbates heart failure or induces a reversible lupus-like syndrome ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 |  Show IntroductionHide Introduction

Safety of Aggressive Statin Therapy

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
. Immunological problems resulting in a lupus-like syndrome have occurred. Statins can also cause acute ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
, including pulmonary infiltrates Occasional: lupus-like syndrome; hematologic abnormalities; hemolytic ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
3 months of treatment. A lupus-like syndrome has been reported. Hemolysis may occur in patients ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, and a lupus-like syndrome have been reported. Nephrotoxicity occurs rarely. An acute intolerance syndrome ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
, systemic lupus erythematosus CYP3A4 inhibitors may increase ethosuximide levels and CYP3A4 inducers ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
minocycline to cause vertigo remains to be estab-lished. Drug-induced lupus and autoimmune hepatitis can ...
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20   doi:10.58347/tml.2024.1695a |  Show IntroductionHide Introduction

Drugs for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019  (Issue 1588)
. Leukopenia, agranulocytosis, reversible oligospermia, a lupus-like syndrome, and hepatotoxicity ...
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Med Lett Drugs Ther. 2019 Dec 30;61(1588):203-10 |  Show IntroductionHide Introduction